

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

**APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND
APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

The Board is pleased to announce that, with effect from September 12, 2024, Dr. Ross Allen Grossman and Dr. Alphonse Galdes have been appointed as a non-executive director and an independent non-executive director of Genscript Biotech Corporation, respectively.

This announcement is made by the board (the “**Board**”) of directors (“**Director(s)**”) of Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Dr. Ross Allen Grossman (“**Dr. Grossman**”) has been appointed as a non-executive Director with effect from September 12, 2024.

The biographical details and other information of Dr. Grossman are set out below:

Dr. Grossman

Dr. Grossman, aged 74, has over 35 years of experience in human resources leadership and consultancy gained from his previous service in senior and executive positions at multinational financial services, pharmaceutical and biotechnology companies in the United States (the “**U.S.**”).

He held various human resources leadership roles at Prudential Financial, Inc. between 1979 and 1998. From 1998 to 2000, he was the chief human resources officer and a member of the Executive Committee for the US pharmaceutical business of Novartis Pharmaceuticals Corporation and served on the Novartis Global HR Leadership Team. Between 2000 and 2002, he joined UBS AG (formerly Paine Webber) as the senior vice president of human resources of the Private Client Group. Between 2002 and 2013, he led the building and formulation of human resources infrastructure, process and strategy at Regeneron Pharmaceuticals (“**Regeneron**”) which resulted in a significant growth in the workforce from a few hundred to over 5,000 employees as Regeneron launched four new products. He retired in December 2013 but rejoined Regeneron in 2015 and retired again in 2016. Dr. Grossman then founded Stony Point Consulting, LLC in 2014, serving as the president, which position he currently holds. Since 2023, Dr. Grossman has served on the Board of

Directors of Velox, Inc., a private global services provider committed to transforming medical technology (MedTech).

Dr. Grossman joined the Group in 2023 and currently serves as a consultant for Legend Biotech Corporation (“**Legend Biotech**”), a non-wholly owned subsidiary of the Company, whose shares are listed on the Nasdaq Global Select Market in the U.S., the position for which he was granted 1,869 restricted shares pursuant to and subject to the terms and conditions of the restricted shares plan approved and adopted by the shareholders of Legend Biotech on May 26, 2020.

Dr. Grossman earned a bachelor’s degree in English from California State University in 1972, a master’s degree in English and American Literature from Claremont Graduate University in 1973, a doctorate in English from Claremont Graduate University in 1976 and a master’s degree in business administration (with a Finance and Marketing concentration) from the University of California, Los Angeles, in 1979.

Dr. Grossman is currently the chairman of the board of trustees and a member of the executive committee of the Keck Graduate Institute in Claremont, California, one of the Claremont Colleges and a graduate university in the U.S. focused on the intersection of business and biotechnology after having served on the board of trustees since 2013. He has also served on the board of trustees and the executive committee of the Center for Excellence in Education in McLean, Virginia, since 2016, which encourages the best young scientists to focus their education and careers on the science, technology, engineering and mathematics (STEM) disciplines.

The Board would like to express its warmest welcome to Dr. Grossman for joining the Board.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Dr. Alphonse Galdes (“**Dr. Galdes**”) has been appointed as independent non-executive Director with effect from September 12, 2024.

The biographical details and other information of Dr. Galdes are set out below:

Dr. Galdes

Dr. Galdes, aged 72, possesses broad experience in drug discovery and biopharmaceutical chemistry and manufacturing and controls (“**CMC**”) development. Dr. Galdes has worked as a director at Galdes Consulting LLC. since 2022, where he provides consulting services on overall, research and development, and CMC strategy for biopharmaceutical clients. Over the course of 27 years from 1995 to 2022, Dr. Galdes progressed towards senior executive positions at Biogen Inc. (NASDAQ: BIIB) (“**Biogen**”), most recently as executive vice president of Pharmaceutical Operations and Technology Division and a member of the executive team between 2019 and 2022. Dr. Galdes’s other prior responsibilities with Biogen include his service as interim senior vice president of the Biotherapeutic and Medicinal Sciences Division between 2016 and 2017, senior vice president of Asset Development and Portfolio Management Division and Pharmaceutical Operations and Technology Division jointly between 2015 and 2019 and senior vice president of Technical Development Pharmaceutical Operations and Technology Division between 2010 and 2015.

Prior to joining Biogen in 1995, Dr. Galdes was a senior director of drug discovery and director of biology at Ohmeda Pharmaceuticals (now part of Baxter HealthCare) from 1992 to 1995, Senior Scientist of Healthcare Research & Development of the BOC Group from 1984 to 1992, and a research associate at the Department of Biological Chemistry at Harvard Medical School from 1979 to 1984.

Dr. Galdes earned a bachelor's degree in chemistry and biology and a master's degree in biochemistry from the University of Malta, Malta, in June 1973 and June 1975 respectively, and a doctorate in biochemistry from the University of Oxford, Oxford, in January 1979, where he was awarded Rhodes Scholarship to The Queen's College in 1975.

The Board would like to express its warmest welcome to Dr. Galdes for joining the Board.

TERM OF APPOINTMENT

Pursuant to the letters of appointment made between the Company and each of Dr. Grossman and Dr. Galdes (collectively, the **"Letters of Appointment"**), the appointments of Dr. Grossman and Dr. Galdes will be for an initial term of three years commencing from September 12, 2024. They are subject to retirement by rotation and are eligible for re-election pursuant to the memorandum of association and the articles of association of the Company and the Listing Rules. Therefore, Dr. Grossman and Dr. Galdes will hold office until the next annual general meeting of the Company at which they will be eligible for re-election.

DIRECTORS' EMOLUMENT

According to the Letters of Appointment, each of Dr. Grossman and Dr. Galdes is entitled to an annual remuneration of US\$100,000 or a pro-rata amount for any incomplete year (among which, at his election, up to US\$30,000, or a pro rata amount for any incomplete year, may be paid in the form of restricted share unit of the equivalent amount for each year of service at such time as the Board, at the recommendation of the remuneration committee of the Company (**"Remuneration Committee"**), may from time to time determine) (the **"RSA Grant"**) and be eligible to participate in the Post-IPO Share Option Scheme (adopted by the Company on December 7, 2015 and amended on June 21, 2024), the 2019 Restricted Share Award Scheme (adopted on March 22, 2019 and amended on June 21, 2024) and the 2021 Restricted Share Award Scheme (adopted by the Company on August 23, 2021 and amended on May 26, 2022 and June 21, 2024 respectively), and the grant of share awards and options is subject to the recommendation by the Remuneration Committee and approval by the Board from time to time (collectively, the **"Remuneration Packages"**). The Remuneration Packages have been recommended by the Remuneration Committee and approved by the Board with reference to their duties and responsibilities in the Company and the prevailing market condition.

CONFIRMATIONS PURSUANT TO RULE 3.09D AND RULE 3.13 OF THE LISTING RULES

Dr. Grossman and Dr. Galdes have obtained legal advice pursuant to Rule 3.09D of the Listing Rules and have confirmed that they understood their obligations as directors of the Company.

The Company has received written confirmation of independence according to Rule 3.13 of the Listing Rules from Dr. Galdes. Dr. Galdes has confirmed (a) his independence as regards to each of the factors contained in Rules 3.13(1) to (8) of the Listing Rules; (b) that he has no past or present financial or other interest in the business of the Company or its subsidiaries nor connection with any core connected persons of the Company; and (c) there are no other factors that may affect his independence at the time of his appointment.

NEGATIVE STATEMENT PURSUANT TO RULE 13.51(2)(x) OF THE LISTING RULES

As at the date of this announcement, Dr. Grossman and Dr. Galdes have respectively confirmed that (i) they do not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) save as disclosed above, neither of them holds any position with the Group; (iii) save as disclosed above, Dr. Grossman and Dr. Galdes do not and have not held any directorship in any public listed companies in Hong Kong or overseas in the past three years nor any other major appointments and qualifications; (iv) they do not have any relationship

with any Directors, senior management, substantial shareholders or controlling shareholders of the Company or its subsidiaries or any of their respective associates (as defined in the Listing Rules) of the Company; (v) there is no other information in relation to Dr. Grossman and Dr. Galdes that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and (vi) there are no other matters that need to be brought to the attention of the shareholders of the Company in connection with Dr. Grossman and Dr. Galdes' appointments as Directors.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

By order of the Board
Genscript Biotech Corporation
Jiange Meng
Chairman and Executive Director

Hong Kong, September 12, 2024

*As at the date of this announcement, the executive Directors are Dr. Fangliang Zhang (“**Dr. Frank Zhang**”), Mr. Jiange Meng (“**Mr. Robin Meng**”), Ms. Ye Wang (“**Ms. Sally Wang**”) and Dr. Li Zhu; the non-executive Directors are Dr. Luquan Wang (“**Dr. Larry Wang**”) and Dr. Ross Allen Grossman; and the independent non-executive Directors are Mr. Zumian Dai (“**Mr. Edward Dai**”), Mr. Jiuan Pan (“**Mr. Ethan Pan**”), Mr. Yiu Leung Andy Cheung, Dr. Chenyang Shi (“**Dr. Victor Shi**”) and Dr. Alphonse Galdes.*